ABBVIE

AbbVie's Phase 2 ELATE trial demonstrated that onabotulinumtoxinA (BOTOX) significantly improved tremor disability scores compared to placebo in patients with upper limb essential tremor.

The U.S. FDA has granted Fast Track Designation to ABBV-CLS-628, an investigational anti-PAPP-A monoclonal antibody developed by Calico and AbbVie for treating ADPKD.

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.

Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.

The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.

The FDA has awarded fast track designation to UB-VV111 for treating relapsed/refractory large B-cell lymphoma and chronic lymphocytic leukemia after at least two prior therapies.

AbbVie has submitted a Biologics License Application to the FDA for pivekimab sunirine, a CD123-targeting antibody-drug conjugate designed to treat Blastic Plasmacytoid Dendritic Cell Neoplasm.

AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S., following President Trump's most-favored-nation pricing policy demands.

Moonlake Immunotherapeutics' experimental drug sonelokimab delivered mixed results in two late-stage hidradenitis suppurativa trials, with one study meeting statistical significance but falling short of investor expectations.

Quebec's RAMQ has added QULIPTA (atogepant) to its formulary for both chronic and episodic migraine prevention, expanding access to this oral CGRP receptor antagonist.